Article 81 Specific criteria on surveillance and biosecurity measures for the maintenance of disease-free status

United Kingdom

The Member States, zones or compartments thereof may maintain disease-free status only if, in addition to the criteria laid down in points (a) and (c) of Article 41(1) of Regulation (EU) 2016/429, they comply with:

(a)

the undertaking of sufficient surveillance activities to enable the early detection of the disease and the demonstration of disease-free status;

(b)

the biosecurity measures ordered by the competent authority based on the risks identified to prevent the introduction of the disease;

(c)

the operational rules as referred to in points (a)(v), a(vi) and a(vii) of Article 66 or points (a)(v), a(vi) and a(vii) of Article 73(1).

In the case of aquatic animals, when a Member State is declared free from one or more of the listed diseases, it may discontinue targeted surveillance as referred to in points (k) to (q) of paragraph 3 and maintain its disease-free status provided that the risk of introduction of the relevant disease has been assessed and conditions conducive to clinical expression of the disease in question exist.

In disease-free zones or compartments in Member States which are not declared disease-free, or in all cases where conditions conducive to clinical expression of the disease in question do not exist, targeted surveillance shall be continued as referred to in points (k) to (q) of paragraph 3.

The disease specific requirements as regards surveillance and biosecurity measures are provided in:

(a)

Section 2 of Chapter 3 of Part I of Annex IV for status free from infection with Brucella abortus, B. melitensis and B. suis as regards kept bovine animals or Section 2 of Chapter 4 of Part I of Annex IV for status free from infection with Brucella abortus, B. melitensis and B. suis as regards kept ovine and caprine animals;

(b)

Section 2 of Chapter 2 of Part II of Annex IV for status free from infection with MTBC;

(c)

Section 2 of Chapter 2 of Part III of Annex IV for status free from EBL;

(d)

Section 2 of Chapter 2 of Part IV of Annex IV for status free from IBR/IPV;

(e)

Section 2 of Chapter 2 of Part V of Annex IV for status free from infection with ADV;

(f)

Section 2 of Chapter 2 of Part VI of Annex IV for status free from BVD;

(g)

Section 2 of Chapter 2 of Part I of Annex V for status free from infection with RABV;

(h)

Section 2 of Chapter 4 of Part II of Annex V for status free from infection with BTV;

(i)

Section 2 of Part III of Annex V for status free from infestation with Varroa spp;

(j)

Section 2 of Part IV of Annex V for status free from infection with Newcastle disease virus without vaccination;

(k)

Section 4 of Chapter 1 of Part II of Annex VI for status free from VHS;

(l)

Section 4 of Chapter 1 of Part II of Annex VI for status free from IHN;

(m)

Section 4 of Chapter 2 of Part II of Annex VI for status free from infection with HPR-deleted ISAV;

(n)

Section 4 of Chapter 3 of Part II of Annex VI for status free from infection with Marteilia refringens;

(o)

Section 4 of Chapter 4 of Part II of Annex VI for status free from infection with Bonamia exitiosa;

(p)

Section 4 of Chapter 5 of Part II of Annex VI for status free from infection with Bonamia ostreae;

(q)

Section 4 of Chapter 6 of Part II of Annex VI for status free from infection with WSSV.